INFORMAZIONI SU QUESTO ARTICOLO
Categoria dell'articolo: Case series
Pubblicato online: 06 nov 2021
Pagine: 312 - 317
Ricevuto: 30 dic 2020
Accettato: 15 giu 2021
DOI: https://doi.org/10.2478/jccm-2021-0019
Parole chiave
© 2021 Melissa Robin Bowman Foster, Ali Atef Hijazi, Rebecca Opoku, Priya Varghese, Chun Li, published by Sciendo
This work is licensed under the Creative Commons Attribution 4.0 International License.
Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Summary of presented case studies of patients receiving specialty hospital’s COVID-19 treatment protocol __
| Case number | Prior treatment | Duration of illness prior to beginning COVID-19 treatment protocol | Number of days on treatment protocol before extubation | Number of days on treatment protocol before discharge to rehabilitation center | Respiratory support at discharge |
|---|---|---|---|---|---|
| 1 | convalascent plasma, tracheotomy, PEG, FIO2 60 - 100%, PEEP | 35 days | 12 days | 24 days | room air |
| 2 | convalascent plasma, tocilizumab | 30 days | 7 days | 10 days | room air |
| 3 | convalescent plasma, remdesivir, dexamethasone | 34 days | 5 days | 10 days | room air |
| 4 | IV heparin, remdesivir, dexamethasone, high flow oxygen 15L (NOTE: NO INTUBATION REQUIRED) | 23 days | N/A - patient did not require intubation | 13 days | 3 L O2 per minute, bilevel positive airway pressure at night |
| 5 | IV antibiotics, dexamethasone, tracheostomy, PEG | 21 days | 16 days | 29 days | 1 L O2 by nasal cannula PRN nightly |
| 6 | convalescent plasma, remdesivir, tocilizumab, FiO2 30%, PEEP | 37 days | 19 days | 28 days | room air |
| 7 | remdesivir, IV steroids, oxymizer 6L per minute | 96 days | N/A - patient extubated prior to starting protocol | 9 days | 2 L by nasal cannula |
| 8 | dexamethasone, remdesivir, ceftriaxone sodium, azithromycin, convalescent plasma | 35 days | 28 days | 33 days | 2 L by nasal cannula PRN |
| 9 | remdesivir, actemra, solumedrol | 63 days | 11 days | 15 days | 2 L by nula nasal PRNcan- |